Bariatric surgery is safe and effective for adolescents, but sex-differences are difficult to examine owing to female predominance in individual studies. We pooled data from four high-quality studies to examine sex-differences among adolescent bariatric surgery. Data from three prospective observational studies and one randomized trial in the United States (Teen-LABS, FABS5+) and Sweden (AMOS, AMOS2), were harmonized. Descriptive statistics explored changes in standard body mass index (BMI) categories over time. We evaluated sex differences in % change in BMI using linear mixed effects models. 389 participants (278 females; 111 males; aged 16.9±1.5 years; 76.6% Non-Hispanic White) were used for analysis. Baseline BMI was 50.5 kg/m2 for females and 53.8 kg/m2 for males with 79.7% having gastric bypass, 16.7% sleeve gastrectomy, and 3.6% gastric banding. Severe obesity was ubiquitous among participants pre-operatively (M: 100%, F: 99.6%). At 24 months, 40%, 35%, 15%, and 6% of males, 29%, 36%, 21%, and 10% of females were in severe obesity, obesity, overweight, and normal weight categories, respectively. Mean BMI change for females and males, respectively was -22.5% and -25.5% at 6 months, -31.59% and -34.15% at 12 months, and -29.68% and -32.73% at 24 months. A greater BMI reduction was observed among males at 6 months (-2.99%, 95%CI: -5.16, -0.81%, p=0.01), 12 months (-2.56%, 95%CI: -4.52, -0.60, p=0.01), and 24 months (-3.05%, 95%CI: -6.09, -0.01, p=0.05). After adjusting for age, race/ethnicity, and types of procedure, a greater BMI reduction among males at 6 months (-1.95%, 95%CI: -3.77, -0.12, p=0.04), 12 months (-2.10%, 95%CI: -3.89, -0.31, p=0.02), and 24 months (-2.45%, 95%CI: -5.34, 0.43, p=0.10) was still observed. While weight loss following bariatric surgery is significant among both sexes up to 2 years, males consistently exhibit somewhat greater BMI reduction. The clinical relevance and mechanisms driving sex-differences warrant further exploration.

Disclosure

S. Jang: None. J. Dahlgren: None. T.M. Jenkins: None. T. Inge: Consultant; Medtronic, Eli Lilly and Company, Brainstorm Therapeutics. Stock/Shareholder; Standard Bariatrics. Consultant; Teleflex. J.R. Ryder: None.

Funding

Funding for Teen-LABS was provided by the National Institutes of Health (NIH) (U01DK072493 / UM1 DK072493 to T.H.I.) (UM1 DK095710 to C.X., T.M.J.) and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (8UL1TR000077). Support also came from National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, (UL1TR000114).

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.